Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8115MR)

This product GTTS-WQ8115MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8115MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13436MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ650MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ6928MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ4459MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ2671MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ1694MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ15MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ1674MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACZ885
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW